Kamada
Update in progressKMDA (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Kamada Ltd. develops, manufactures and distributes plasma‑derived protein therapeutics and related biopharmaceuticals. Its products include KAMRAB/KEDRAB for rabies prophylaxis; CYTOGAM for CMV prophylaxis in transplant patients; VARIZIG for varicella exposure; WINRHO SDF for ITP; HEPAGAM B for hepatitis B prevention; GLASSIA for alpha-1 antitrypsin deficiency; RUCONEST for angioedema; IVIG and BEVACIZUMAB KAMADA, among others. Based in Rehovot, Israel, founded in 1990.
Company score
- Sentiment
- 0.48
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.17
- Governance
- 0.15
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.28
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Loading section